drugset
drugset / Trial / NCT04153799

Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer

NCT04153799 ↗

Phase 1 Unknown 11 enrolled Sun Yat-sen University Guangzhou Bio-gene Technology Co., Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is a clinical study on the safety, efficacy and I phase of single center, single arm, open-dose climbing, intravenous infusion of Anti- Epidermal growth factor receptor(EGFR) Chimeric Antigen Receptor(CAR) T cells modified by C-X-C Chemokine receptor type 5(CXCR 5) in patients with advanced adult non-small cell lung cancer(NSCLC).

Timeline

Start
2019-11-01
Primary completion
2021-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells Cell therapy 500000 cells/kg Intravenous
Subject CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells Cell therapy 1.58e+06 cells/kg Intravenous
Subject CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells Cell therapy 5e+06 cells/kg Intravenous

Indications

non-small cell lung carcinoma